Live
FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentFierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffClinical OMICsRewriting Cancer Care Through EpigeneticsFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharmaBioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitorsBioWorldCaregen reports new GLP-1R agonistsBioWorldIteos Belgium discloses new PTPN1/2 inhibitorsBioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIVBioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patent
Eli Lilly 30 avr. 2026

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket - Barron's

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket - Barron's

Contenu indisponible. Consultez la source originale.